Comanche Biopharma Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series B2
- Latest Deal Amount
-
$10M
- Investors
-
8
Comanche Biopharma General Information
Description
Operator of a biopharmaceutical company intended to develop an investigational siRNA medicine for preterm preeclampsia. The company provides access to evidence-based and affordable therapies for treating life-threatening complications of pregnancy, enabling women to avail themselves of cost-effective and sustainable preeclampsia treatment at its root cause.
Contact Information
Website
www.comanchebiopharma.comCorporate Office
- 50 Beharrell Street
- Unit B
- Concord, MA 01742
- United States
Corporate Office
- 50 Beharrell Street
- Unit B
- Concord, MA 01742
- United States
Comanche Biopharma Timeline
Comanche Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B2) | 15-Oct-2025 | $10M | Completed | Generating Revenue | ||
| 2. Early Stage VC (Series B) | 17-Jan-2024 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 28-Jun-2021 | $36.1M | $36.1M | Completed | Startup |
Comanche Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A | 33,341,024 | $0.010000 | 8% | $1.08 | $1.08 | 1x | $1.08 | 25.79% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Comanche Biopharma Patents
Comanche Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024296743-A1 | Formulations of nucleic acid compounds and uses thereof | Pending | 13-Jul-2023 | ||
| EP-4743061-A1 | Formulations of nucleic acid compounds and uses thereof | Pending | 13-Jul-2023 | ||
| US-20260248839-A1 | Formulations of nucleic acid compounds and uses thereof | Pending | 13-Jul-2023 | ||
| WO-2025015189-A1 | Formulations of nucleic acid compounds and uses thereof | Inactive | 13-Jul-2023 | A61K9/0019 |
Comanche Biopharma Signals
Comanche Biopharma Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Atlas Venture | Venture Capital | Minority | ||
| LAV (Lilly Asia Fund) | Corporate Venture Capital | Minority | ||
| Longview Healthcare Ventures | Venture Capital | Minority | ||
| New Enterprise Associates | Venture Capital | Minority | ||
| Broadview Ventures | Venture Capital | Minority |
Comanche Biopharma FAQs
-
When was Comanche Biopharma founded?
Comanche Biopharma was founded in 2020.
-
Where is Comanche Biopharma headquartered?
Comanche Biopharma is headquartered in Concord, MA.
-
What is the size of Comanche Biopharma?
Comanche Biopharma has 29 total employees.
-
What industry is Comanche Biopharma in?
Comanche Biopharma’s primary industry is Drug Discovery.
-
Is Comanche Biopharma a private or public company?
Comanche Biopharma is a Private company.
-
What is the current valuation of Comanche Biopharma?
The current valuation of Comanche Biopharma is .
-
What is Comanche Biopharma’s current revenue?
The current revenue for Comanche Biopharma is .
-
How much funding has Comanche Biopharma raised over time?
Comanche Biopharma has raised $136M.
-
Who are Comanche Biopharma’s investors?
Atlas Venture, LAV (Lilly Asia Fund), Longview Healthcare Ventures, New Enterprise Associates, and Broadview Ventures are 5 of 8 investors who have invested in Comanche Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process